Brus Christina, Saif Muhammad Wasif
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
JOP. 2010 Jul 5;11(4):321-3.
Most patients with adenocarcinoma of the pancreas present with locally advanced or metastatic disease. Although single agent gemcitabine is widely accepted as first-line therapy, there is no current standard of care for gemcitabine-refractory patients. Common second-line chemotherapy regimens included oxaliplatin and 5-FU/leucovorin (OFF), gemcitabine and oxaliplatin (GEMOX), oxaliplatin and capecitabine (XELOX), and irinotecan-oxaliplatin. At the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, several new second-line chemotherapy regimens were presented, including gemcitabine and oxaliplatin with imatinib, single agent nab-paclitaxel, and the combination of high-dose capecitabine with oxaliplatin and sorafenib. These abstracts provide exciting new directions for the treatment of gemcitabine-refractory advanced pancreatic cancer.
大多数胰腺癌腺癌患者就诊时已处于局部晚期或发生转移。尽管单药吉西他滨被广泛认可为一线治疗药物，但目前对于吉西他滨耐药患者尚无标准治疗方案。常见的二线化疗方案包括奥沙利铂和5-氟尿嘧啶/亚叶酸钙（OFF）、吉西他滨和奥沙利铂（GEMOX）、奥沙利铂和卡培他滨（XELOX）以及伊立替康-奥沙利铂。在2010年美国临床肿瘤学会（ASCO）年会上，展示了几种新的二线化疗方案，包括吉西他滨和奥沙利铂联合伊马替尼、单药纳米白蛋白结合型紫杉醇，以及高剂量卡培他滨联合奥沙利铂和索拉非尼。这些摘要为吉西他滨耐药的晚期胰腺癌治疗提供了令人振奋的新方向。
